NDA 018936 · Eli Lilly and CO
Sarafem
Fluoxetine Hydrochloride · Oral
NovelPriority reviewDiscontinuedLast checked: Nov 20, 2026Latest source record: Aug 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1987
Dec 29, 1987
Approved uses
10
Original approval plus efficacy supplements
Registered trials
326
58 Phase 3, 28 recruiting
FAERS reports
63,050
39,616 serious, 3,988 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions ( 5.1 )] . In patients of all ages who are started on antidepressant therapy, monitor closely for worsening and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions ( 5.1 )] . PROZAC is not approved for use in children less than 7 years of age [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.4 )] . When using PROZAC...
What it is approved for
From the label in effect Jan 8, 2026.
PROZAC ® is indicated for the treatment of: Acute and maintenance treatment of Major Depressive Disorder [see Clinical Studies ( 14.1 )] . Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) [see Clinical Studies ( 14.2 )]. Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa [see Clinical Studies ( 14.3 )] . Acute treatment of Panic Disorder, with or without agoraphobia [see Clinical Studies ( 14.4 )]. PROZAC and Olanzapine in Combination is indicated for the treatment of: Acute treatment of depressive episodes associated with Bipolar I Disorder. Treatment resistant depression (Major Depressive Disorder in patients, who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). PROZAC monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant depression. When using PROZAC and olanzapine in combination, also refer to the Clinical Studies section of the package insert for Symbyax ® . PROZAC ® is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) ( 1 ) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) ( 1 ) Acute and maintenance treatment of Bulimia Nervosa ( 1 ) Acute treatment of Panic Disorder, with or without agoraphobia ( 1 ) PROZAC and olanzapine in combination for treatment of: Acute Depressive Episodes Associated with Bipolar I Disorder ( 1 ) Treatment Resistant Depression ( 1 )
Mechanism: Although the exact mechanism of PROZAC is unknown, it is presumed to be linked to its inhibition of CNS neuronal uptake of serotonin.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 10, 2014 Supplement 102 · Efficacy LabelLetter
- Jul 26, 2013 Supplement 101 · Efficacy LetterLabel
- Mar 19, 2009 Supplement 77 · Efficacy · priority review LabelLetter
- Jan 3, 2003 Supplement 64 · Efficacy LabelLetterReview
- Jul 29, 2002 Supplement 65 · Efficacy Review
- Jul 29, 2002 Supplement 61 · Efficacy Label
- Jun 12, 2002 Supplement 67 · Efficacy LetterLabel
- Jul 6, 2000 Supplement 58 · Efficacy LetterLabel
- Nov 21, 1996 Supplement 4 · Efficacy
- Dec 29, 1987 Original approval · Type 1 - New Molecular Entity · priority review Other Important Information from FDA
6 products under this application
- SARAFEM · FLUOXETINE HYDROCHLORIDE EQ 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
- PROZAC · FLUOXETINE HYDROCHLORIDE EQ 10MG BASE · CAPSULE, ORAL · Discontinued · TE AB1
- PROZAC · FLUOXETINE HYDROCHLORIDE EQ 60MG BASE · CAPSULE, ORAL · Discontinued
- SARAFEM · FLUOXETINE HYDROCHLORIDE EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
- PROZAC · FLUOXETINE HYDROCHLORIDE EQ 40MG BASE · CAPSULE, ORAL · Discontinued · TE AB
- PROZAC · FLUOXETINE HYDROCHLORIDE EQ 20MG BASE · CAPSULE, ORAL · Discontinued · TE AB1
Clinical trials
Interventional ClinicalTrials.gov studies with "Fluoxetine" as an intervention, any sponsor and status, largest first.
- Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild SymptomsPivotal-lookingStatus unknown
CardresearchAcademic, hospital or other
NCT04727424 · 7,819 participants (planned) · Start Jan 19, 2021 · Primary completion Jun 1, 2024
Drug: Budesonide Powder; Fluoxetine 20 MG and 1 more · For: Covid19; SARS-Associated Coronavirus
Sites: Belo Horizonte, Brazil; Betim, Brazil; Brumadinho, Brazil · 12 sites in all
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)Pivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT05041907 · 3,800 participants (planned) · Start Sep 30, 2021 · Primary completion Jan 2027
Drug: Nirmatrelvir/ritonavir (e.g. PAXLOVID™); Nitazoxanide and 16 more · For: COVID-19
Sites: Minas Gerais, Brazil; Vientiane, Laos; Kathmandu, Nepal · 7 sites in all
- Study of Neuro-Cognitive Correlates of Pediatric Anxiety DisordersPivotal-lookingRecruiting
National Institute of Mental Health (NIMH)NIH
NCT00018057 · 3,500 participants (planned) · Start Oct 2, 2001 · Primary completion Jan 1, 2029
Drug: Fluoxetine · For: Anxiety Disorders; Major Depressive Disorder
Sites: Bethesda, Maryland; College Park, Maryland
- Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01360866 · 2,944 participants · Start Oct 2011 · Primary completion Apr 18, 2017
Drug: OPC-34712; Escitalopram and 5 more · For: Depressive Disorder; Depression; Depressive Disorder, Major and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 142 sites in all
- SMART-DAPPER: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research ProjectPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT03466346 · 2,162 participants · Start Aug 31, 2020 · Primary completion May 6, 2024
Drug: Fluoxetine · For: Depression, Unipolar; Posttraumatic Stress Disorder; Trauma
Sites: Kisumu, Kenya · 3 sites in all
- Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentPivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT01838681 · 1,986 participants · Start Jun 2013 · Primary completion Jun 2016
Drug: Placebo; Brexpiprazole and 1 more · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Cerritos, California; Temecula, California · 107 sites in all
- Efficacy of Fluoxetine - a Trial in StrokePivotal-lookingCompleted
Karolinska InstitutetAcademic, hospital or other
NCT02683213 · 1,500 participants · Start Oct 20, 2014 · Primary completion Jun 2020
Drug: Fluoxetine; Placebo · For: Stroke
Sites: Stockholm, Sweden
- Improving Outcomes in Depression in Primary Care in a Low Resource SettingPivotal-lookingActive, not recruiting
Harvard Medical School (HMS and HSDM)Academic, hospital or other
NCT05944926 · 1,500 participants (planned) · Start Mar 18, 2024 · Primary completion Apr 10, 2026
Drug: Antidepressant medication (fluoxetine) · For: Depression; Depressive Disorder
Sites: Bhopal, India
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4,661
- fatigue4,344
- nausea4,301
- headache3,758
- depression3,706
- anxiety3,422
- pain3,103
- dizziness2,925
- diarrhoea2,863
- off label use2,734
- insomnia2,671
- dyspnoea2,641
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,705 |
| 2005 | 1,710 |
| 2006 | 1,680 |
| 2007 | 1,443 |
| 2008 | 1,409 |
| 2009 | 1,920 |
| 2010 | 2,252 |
| 2011 | 2,519 |
| 2012 | 3,268 |
| 2013 | 2,581 |
| 2014 | 2,868 |
| 2015 | 5,363 |
| 2016 | 4,442 |
| 2017 | 3,305 |
| 2018 | 3,296 |
| 2019 | 3,332 |
| 2020 | 2,801 |
| 2021 | 2,462 |
| 2022 | 3,084 |
| 2023 | 2,963 |
| 2024 | 3,226 |
| 2025 | 3,036 |
| 2026 | 2,383 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Prozac (Fluoxetine HCl)
2024 spending
$15.6M
Beneficiaries
2,183
11,749 claims
Per beneficiary
$7,169
$17.78 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $25,021,067 |
| 2021 | $23,665,005 |
| 2022 | $23,441,957 |
| 2023 | $22,023,208 |
| 2024 | $15,649,211 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis.
Nuñez NA, Joseph B, Pahwa M, et al. · J Affect Disord 2022 · Network Meta-Analysis, Research Support, N.I.H., Extramural
- Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis.
Zhou X, Teng T, Zhang Y, et al. · Lancet Psychiatry 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis.
Furukawa TA, Cipriani A, Cowen PJ, et al. · Lancet Psychiatry 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Antidepressants for smoking cessation.
Hughes JR, Stead LF, Lancaster T · Cochrane Database Syst Rev 2003 · Meta-Analysis, Systematic Review
- Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
March J, Silva S, Petrycki S, et al. · JAMA 2004 · Clinical Trial, Multicenter Study
- Systematic review and guide to selection of selective serotonin reuptake inhibitors.
Edwards JG, Anderson I · Drugs 1999 · Comparative Study, Meta-Analysis
Sponsor: Eli Lilly · Also marketed as Prozac
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.